These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 34914074)

  • 1. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.
    Roesler AS; Anderson KS
    Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
    Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
    J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
    Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
    Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants for Neoantigen Identification.
    Garcia-Garijo A; Fajardo CA; Gros A
    Front Immunol; 2019; 10():1392. PubMed ID: 31293573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
    Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
    Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
    De Mattos-Arruda L; Vazquez M; Finotello F; Lepore R; Porta E; Hundal J; Amengual-Rigo P; Ng CKY; Valencia A; Carrillo J; Chan TA; Guallar V; McGranahan N; Blanco J; Griffith M
    Ann Oncol; 2020 Aug; 31(8):978-990. PubMed ID: 32610166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-level distribution and putative immunogenicity of cancer neoepitopes.
    Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
    BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
    Perumal D; Imai N; Laganà A; Finnigan J; Melnekoff D; Leshchenko VV; Solovyov A; Madduri D; Chari A; Cho HJ; Dudley JT; Brody JD; Jagannath S; Greenbaum B; Gnjatic S; Bhardwaj N; Parekh S
    Clin Cancer Res; 2020 Jan; 26(2):450-464. PubMed ID: 31857430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prioritizing candidate peptides for cancer vaccines through predicting peptide presentation by HLA-I proteins.
    Zhou LY; Zou F; Sun W
    Biometrics; 2023 Sep; 79(3):2664-2676. PubMed ID: 35833513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
    Chen I; Chen MY; Goedegebuure SP; Gillanders WE
    Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
    [No Abstract]   [Full Text] [Related]  

  • 14. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
    Mørk SK; Kadivar M; Bol KF; Draghi A; Westergaard MCW; Skadborg SK; Overgaard N; Sørensen AB; Rasmussen IS; Andreasen LV; Yde CW; Trolle T; Garde C; Friis-Nielsen J; Nørgaard N; Christensen D; Kringelum JV; Donia M; Hadrup SR; Svane IM
    Oncoimmunology; 2022; 11(1):2023255. PubMed ID: 35036074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor neoantigens: Novel strategies for application of cancer immunotherapy.
    Guan H; Wu Y; Li LU; Yang Y; Qiu S; Zhao Z; Chu X; He J; Chen Z; Zhang Y; Ding H; Pan J; Pan Y
    Oncol Res; 2023; 31(4):437-448. PubMed ID: 37415744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best practices for bioinformatic characterization of neoantigens for clinical utility.
    Richters MM; Xia H; Campbell KM; Gillanders WE; Griffith OL; Griffith M
    Genome Med; 2019 Aug; 11(1):56. PubMed ID: 31462330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy.
    Wu Y; Feng L
    Expert Opin Drug Deliv; 2023 Mar; 20(3):323-333. PubMed ID: 36634017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.
    Lam H; McNeil LK; Starobinets H; DeVault VL; Cohen RB; Twardowski P; Johnson ML; Gillison ML; Stein MN; Vaishampayan UN; DeCillis AP; Foti JJ; Vemulapalli V; Tjon E; Ferber K; DeOliveira DB; Broom W; Agnihotri P; Jaffee EM; Wong KK; Drake CG; Carroll PM; Davis TA; Flechtner JB
    Cancer Discov; 2021 Mar; 11(3):696-713. PubMed ID: 33504579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.